pumps anchored in parallel in the descending aorta. The design is expected to increase accessibility by enabling safe percutaneous implantation to support both renal and cardiac function, with low risk of bleeding, stroke, and pump thrombosis, while providing sustained symptom relief, reduced re-hospitalizations and improved overall quality of life. To date, Puzzle Medical has successfully:

○ completed its first-in-human study with all patients experiencing improvements in cardiac and kidney function (2022); ○ completed a Seed financing round (2021); ○ built a strong Key Opinion Leaders committee (2021); ○ received U.S. Food and Drug Administration (FDA) Breakthrough Device Designation (2021).